secwatch.observer — SEC 8-K summary
======================================

Issuer:     Esperion Therapeutics, Inc. (ESPR)
CIK:        0001434868
Form:       8-K
Filed at:   2026-03-10T23:59:59+00:00
Accession:  0001628280-26-016230
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Esperion Q4 rev $168.4M (+144% Y/Y); FY25 rev $403.1M; Q4 net income $61.8M; acquires Corstasis
--------------------------------------------------------------------------------

- U.S. net product revenue Q4 $43.7M (+38% Y/Y); FY25 $159.6M (+38% Y/Y).
- Collaboration revenue Q4 $124.7M (includes $90M Otsuka milestone); FY25 $243.6M (+12% Y/Y).
- Q4 net income $61.8M ($0.26 basic EPS vs loss $0.11 in Q4 2024); FY25 net loss $22.7M narrowed from $51.7M.
- Agreed to acquire Corstasis Therapeutics (Enbumyst nasal spray for CHF edema); targets $4B U.S. market.
- Patent settlements restrict generic entry until April 2040; FY26 opex guidance $225-255M (incl ~$15M non-cash).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026016230/0001628280-26-016230-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434868/000162828026016230/espr-20260310.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-016230

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer